What changed: Resectable stage I to III non-small-cell lung cancer
Every dated change on the records linked to Resectable stage I to III non-small-cell lung cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Regulatory1Trial result8Milestone9This record1
September 2026 · 1
2024 · 1
October 2023 · 1
2023 · 4
- 2023Trial resultALINAALINA reported
DFS HR 0.
- 2023Trial resultCALGB 140503 (Alliance)CALGB 140503 (Alliance) reported
5-year disease-free survival 63.
- 2023Trial resultKEYNOTE-671KEYNOTE-671 reported
EFS HR 0.
- 2023MilestoneKEYNOTE-671KEYNOTE-671 and AEGEAN: perioperative pembrolizumab and durvalumab; CALGB 140503: sublobar resection non-inferior
A milestone in how this cancer is treated.
2022 · 2
2021 · 1
2020 · 2
2019 · 1
2015 · 1
2011 · 2
- 2011Trial resultNLST & NELSON (low-dose CT screening)NLST & NELSON (low-dose CT screening) reported
Lung cancer mortality reduced 20% (NLST) and 24% in men (NELSON).
- 2011MilestoneNLST & NELSON (low-dose CT screening)NLST: low-dose CT screening cuts lung cancer mortality by 20 percent, finding more early-stage tumours
A milestone in how this cancer is treated.